Interview: Gou Jen Wang – Co-Founder & Bing Chen Gu – General Manager, Vida BioTechnology, Taiwan

20.06.2017
Gou Jen Wang, the co-founder of Vida BioTechnology, and Bing Chen Gu, General Manager elaborate on how Vida BioTechnology provides added value to its customers by focusing on simplified use, innovation, lower cost and quality in next generation biosensing. Vida BioTechnology was founded in 2014. Can you introduce your company to our readers? What was your vision at the time you started the company and what was the market opportunity you identified?
"We believe in the power of nanotechnology."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Taiwan, Vida BioTechnology, Biotech, Biosensing, R&D, Innovation

Related Interviews

Johnsee Lee – Chairman & CEO & Eric Yang – VP, Quark…

Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how it differs from sequencing technologies in terms of cost and speed,…

Louis Cheng – CEO, Leadgene Biomedical, Taiwan

Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have…

Charles Chen – Vice Chairman & CEO, Medigen Vaccine Biologics Corp.…

Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are.    At MVC we have…

Related Articles

China / BioNTech-Fosun JV; Patent Law Revamp; Hong Kong as a Biotech Listing Hub

The latest news from Chinese pharma, including an overhaul of the country’s patent law; a BioNTech-Fosun tie-up on COVID-19 vaccines; and big R&D subsidies for local companies available in Shanghai.…

Precision Medicine in Asia / More Regional Cooperation Needed

With Asia covering 60 percent of the world’s population but accounting for just around 30 percent of global pharma spending, it goes without saying that healthcare needs in the region…

First Impressions / Taiwanese Pharma

Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that is the envy of its neighbours. Here, three country managers for…

Latest Report

Denmark Pharma Report 2021

Related Content

Taiwan
Vida BioTechnology
Biotech
Biosensing
R&D
Innovation